Research Development Foundation

Baylor College of Medicine

The University of Texas System

Pulmotect, Inc.

Brian E Gilbert

J Vernon Knight

Nadezhda Koshkina

J Clifford Waldrep

E Lynn Zechiedrich

Jonathan Fogg

Daniel James Catanese, Jr

Erol Bakkalbasi

Beppino C Giovanella

Kapil Mehta

Burton F Dickey

Michael J Tuvim

Scott E Evans

Clyde W Wellen

Howard R Six

Samuel Z Wilson

Brenton Scott

Jack V Knight

Philip R Wyde

Diane Markesich

Claire F Verschraegen

Ranjani Parthasarathy

Jr Daniel James Catanese

Embodiments are directed to compositions and methods for treating viral infections.

Compositions and methods for treating viral infections through stimulated innate immunity in combination with antiviral compounds

The present invention relates to nucleic acid molecule compositions comprising minivectors encoding a nucleic acid sequence and methods of gene therapy using minivectors encoding a nucleic acid sequence.

Supercoiled minicircle DNA for gene therapy applications

The present invention relates to nucleic acid molecule compositions comprising MiniVectors&#x2122; encoding a nucleic acid sequence and methods of gene therapy using MiniVectors encoding a nucleic acid sequence.

Supercoiled minivectors for gene therapy applications

Supercoiled minivectors&#x2122; for gene therapy applications

Provided herein is a method of treating primary lung cancer or metastatic cancer to the lung in an individual by delivering at least once to the respiratory tract of the individual via inhalation a nebulized liposomal aerosol comprising a dilauroylphosphatidylcholine liposome containing camptothecin or a derivative thereof in an amount sufficient to deliver a pharmacologically effective dose of the camptothecin or its derivative to treat the cancer. Also provided is a nebulized liposomal aerosol comprising the DLPC containing the camptothecin or its derivative and a method of making the liposome-drug comprising the aerosol.

Small particle liposome aerosols for delivery of anticancer drugs

The small particle liposome aerosol compounds and methods of treatment of the present invention involve lipid- or water soluble anti-cancer drugs incorporated into liposomes. The liposomes are administered in aqueous dispersions from a jet nebulizer to the respiratory tract of an individual. Various anti-cancer drugs may be used, including 20-S-Camptothecin, 9-Nitro-camptothecin, 9-Amino-camptothecin, 10, 11-methylenedioxy-camptothecin and taxol or its derivatives. Administration of these drugs by inhalation provides faster and more efficient absorption of the anticancer drug than does intramuscular administration or oral administration.

Small particle liposome aerosols for delivery of anti-cancer drugs

The small particle liposome or lipid complex aerosol compounds and methods of treatment of the present invention involve lipid- or water soluble anti-cancer drugs incorporated into liposomes or other lipid complexes. The liposomes and complexes are administered in aqueous dispersions from a jet nebulizer to the respiratory tract of an individual. Various anti-cancer drugs may be used, including 20-S-Camptothecin, 9-Nitro-camptothecin, 9-Amino-camptothecin, 10, 11-methylenedioxy-camptothecin and taxol or its derivatives. Administration of these drugs by inhalation provides faster and more efficient absorption of the anticancer drug than does intramuscular administration or oral administration.

Composition for treating cancer via liposomal aerosol formulation containing taxol

To optimize the delivery of all-trans retinoic acid to lung tissue, the potential of vehiculating this drug in liposomes and delivering it via aerosol was determined. Liposomes provide a means to prevent local irritation of lung tissue, reduce pulmonary toxicity, prolong therapeutic levels, and generate high drug concentrations at the tumor sites. Therefore, the delivery of ATRA to the lung tissue in mice was accomplished by nebulization of L-ATRA. The liposomes in the aerosol were uniform, stable, and retained the drug well. The drug was effectively delivered at high concentrations to the lungs of mice and was retained at least up to 96 h after a single exposure to L-ATRA aerosols. The aerosol-delivered ATRA was biologically active as demonstrated by its ability to induce the expression of tissue-type transglutaminase. Aerosol delivery of L-ATRA offers an effective way to deliver high levels of ATRA to the lung without apparent pulmonary toxic effects.

Liposomal aerosols for delivery of chemotherapeutic retinoids to the lungs

Disclosed are aqueous aerosol droplets containing liposome or interacted liposome-drug or medication combination particles in a continuous phase of air or oxygen-enriched air advantageous for the treatment of a wide variety of diseases. The drug or medication is interacted with the liposome membrane so that on its rupture the drug or medication is not lost from the liposome. Different methods of preparation of the aerosol particles containing the liposome and interacted liposome-drug combination particles are described which can be used in small particle aerosol treatment. The majority of the aerosol droplets containing the liposome particles alone or with drugs has a diameter less than 5 microns and has an aerodynamic mass median diameter ranging from about 1 to 3 microns, and the liposome and interacted-liposome drug particles are substantially uniform in size and less than 1 micron in diameter.

Small particle aerosol liposome and liposome-drug combinations for

Growing community of inventors

Houston, TX, United States of America

Brian E Gilbert